Company Overview and News

0
American Water to Invest $17M for Improvement of Water Mains

2018-06-19 zacks
American Water Works’ (AWK - Free Report) subsidiary — Illinois American Water — recently announced plans to invest approximately $16.96 million to improve water service distribution systems. In particular, investment of $14 million has been allotted for the installation and replacement of water main in Peoria District, $2.3 million in Pekin and $0.65 million in Lincoln to upgrade the distribution system.
CTWSP CTWSO WTR CTWS

0
CTWS / Connecticut Water Service, Inc. 425 (Prospectus)

2018-06-19 sec.gov
425 Filed by: Connecticut Water Service, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
CTWS

0
CTWS / Connecticut Water Service, Inc. 425 (Prospectus)

2018-06-18 sec.gov
425 Filed by: Connecticut Water Service, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
CTWS

0
CTWS / Connecticut Water Service, Inc. FORM 8-K (Current Report)

2018-06-18 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CTWS

0
Top Water Utility Stocks For Dividend Growth And Income

2018-06-15 seekingalpha
This article will share my watch list for the sector and present my top three picks at current prices.
CTWSP CTWSO WTR CTWS CWT SJW

3
Eversource Reaffirms Offer to Acquire Connecticut Water

2018-06-14 zacks
Eversource Energy (ES - Free Report) has reaffirmed its original offer to acquire Connecticut Water Service, Inc. at $63.50 per share in cash or Eversource shares. Eversource’s earlier offer was rejected by management of Connecticut Water Service, citing that it was inferior to the offer made by SJW Group (SJW - Free Report) . (Read more: :Connecticut Water Loyal to SJW Group, Rejects Eversource Bid)
CTWSP CTWSO ES CTWS CSX MGYTF

1
Aqua America (WTR) Unit to Buy Limerick's Wastewater Assets

2018-06-12 zacks
Aqua America (WTR - Free Report) announced that its subsidiary, Aqua Pennsylvania, has reached a joint settlement agreement to buy the wastewater assets of Limerick Township. If the agreement is approved by the Pennsylvania Public Utility Commission, it will add nearly 5,400 wastewater customers to Aqua America’s customer base. Aqua America has been expanding its customer base through acquisitions, partnerships and organic growth.
CTWSP CTWSO ES WTR CTWS UTX CWT

0
Deals of the day-Mergers and acquisitions

2018-06-12 reuters
June 12 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:
CTWSP CTWSO SSREY CTWS SSREF

0
California utilities regulator tells SJW to seek merger approval

2018-06-11 reuters
NEW YORK (Reuters) - California’s utilities regulator has told SJW Group (SJW.N) it must seek approval for its proposed merger with Connecticut Water Service Inc (CTWS.O), according to a document provided by the regulator to Reuters, a move that creates a potentially significant impediment to the deal.
CTWSP CTWSO ES CTWS

28
California Water (CWT) Makes Offer to SJW Group Shareholders

2018-06-11 zacks
California Water Service Group (CWT - Free Report) announced that the company has commenced the procedure of tender offer for the acquisition of SJW Group (SJW - Free Report) . The offer entails the company to acquire all the outstanding shares of SJW Group for an all-in-cash price of $68.25 per share, at a 6.1% premium from the price on the date of offer. The purchase price offered to SJW Group’s shareholders represents a 30% premium and exceeds the all-time high of its closing share price when California Water Service made the buyout proposal on Apr 4, 2018.
WFC WFCNP CTWSP WFC.WS CTWSO CTWS WFC.PRL WFC.PRJ CWT WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

0
The Art Of The M&A Deal - Connecticut Water Service

2018-06-11 seekingalpha
Connecticut Water Service is trading at a discount to deal closing, even with removal of the buoy inflating the price of SJW Group.
CTWSP CTWSO ES CTWS SJW CWT

0
CTWS / Connecticut Water Service, Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CTWS

0
CTWS / Connecticut Water Service, Inc. 425 (Prospectus)

2018-06-11 sec.gov
425 Filed by: Connecticut Water Service, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
CTWS

0
CTWS / Connecticut Water Service, Inc. 425 (Prospectus)

2018-06-06 sec.gov
425 Filed by: Connecticut Water Service, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
CTWS

0
CTWS / Connecticut Water Service, Inc. 8-K (Current Report)

2018-06-06 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CTWS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...